• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Polyrizon Ltd. - Ordinary Shares (NQ:PLRZ)

    1.140 -0.030 (-2.56%)
    Streaming Delayed Price Updated: 12:11 PM EDT, Oct 15, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Polyrizon Ltd. - Ordinary Shares

    < Previous 1 2 3 4 5 6 Next >
    Polyrizon Ltd. Announces $17.0 Million Private Placement
    From Polyrizon Ltd.
    Via GlobeNewswire
    Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
    From Polyrizon Ltd.
    Via GlobeNewswire
    Top movers in Tuesday's after hours session
    Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
    Via Chartmill
    12 Health Care Stocks Moving In Tuesday's After-Market Session
     
    Via Benzinga
    Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment
    From Polyrizon Ltd.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
     
    Via Benzinga
    Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
     
    Via Benzinga
    Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
    From Polyrizon Ltd.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
     
    Via Benzinga
    Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
    From Polyrizon Ltd.
    Via GlobeNewswire
    Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
    From Polyrizon Ltd.
    Via GlobeNewswire
    Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
    From Polyrizon Ltd.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
     
    Via Benzinga
    Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
    From Polyrizon Ltd.
    Via GlobeNewswire
    Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
    From Polyrizon Ltd.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
     
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
     
    Via Benzinga
    Why Is Development-Stage Biotech Company Polyrizon Stock Surging Today?
    Polyrizon shares rise after disclosing the publication of a national phase patent application for nasal protection and drug delivery technologies. 
    Via Benzinga
    Topics Intellectual Property
    Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies
    From Polyrizon Ltd.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
     
    Via Benzinga
    Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
    From Polyrizon Ltd.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
     
    Via Benzinga
    Crude Oil Gains Over 1%, General Mills Shares Fall
     
    Via Benzinga
    What's Going On With Polyrizon Shares Wednesday?
    Polyrizon shares are moving higher after the company announced it secured a manufacturing agreement with Eurofins CDMO Amatsiaquitaine. 
    Via Benzinga
    Dow Surges 150 Points, US Current Account Deficit Widens In Q3
     
    Via Benzinga
    Topics Stocks
    Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
    From Polyrizon Ltd.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
     
    Via Benzinga
    Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
    From Polyrizon Ltd.
    Via GlobeNewswire
    Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
    From Polyrizon Ltd.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.